Vaccinex, which is developing antibody therapies to combat cancer and neurological diseases, raised $40 million by offering 3.3 million shares at $12, the low end of the range of $12 to $15. Vaccinex plans to list on the Nasdaq under the symbol VCNX. Oppenheimer & Co. and BTIG acted as lead managers on the deal.